{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T15:26:33Z","timestamp":1780673193361,"version":"3.54.1"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2019.00177","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T11:20:51Z","timestamp":1565176851000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Serological Biomarkers in Early Axial Spondyloarthritis During 24-Months Follow Up (Italian Arm of Space Study)"],"prefix":"10.3389","volume":"6","author":[{"given":"Mariagrazia","family":"Lorenzin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusta","family":"Ortolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Felicetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Favero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Vio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Zaninotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Polito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cosma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanna","family":"Scapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Lacognata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Ramonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,8,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1136\/ard.2009.108217","article-title":"The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of spondyloarthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1136\/ard.2009.110767","article-title":"Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS\/OMERACT MRI group","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.autrev.2016.02.002","article-title":"An update on biomarkers in axial spondyloarthritis","volume":"15","author":"Prajzlerov\u00e1","year":"2016","journal-title":"Autoimmun Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"h5079","DOI":"10.1136\/bmj.h5079","article-title":"Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?","volume":"351","author":"Mohan","year":"2015","journal-title":"BMJ."},{"key":"B9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/ard.2010.138883","article-title":"ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNF\u03b1 inhibitors","volume":"70","author":"Pedersen","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1002\/art.30627","article-title":"Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor \u03b1 inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover","volume":"63","author":"Pedersen","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s10067-015-2949-3","article-title":"Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis","volume":"34","author":"Reveille","year":"2015","journal-title":"Clin Rheumatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/art.24838","article-title":"Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis","volume":"61","author":"De Vries","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1136\/ard.2009.120139","article-title":"Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis","volume":"69","author":"Poddubnyy","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1136\/ard.2007.071605","article-title":"Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab","volume":"67","author":"Visvanathan","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4081\/reumatismo.2017.977","article-title":"Biomarkers, imaging and disease activity indices in patients with early axial spondyloarthritis: the Italian arm of the SpondyloArthritis-Caught-Early (SPACE) Study","volume":"69","author":"Lorenzin","year":"2017","journal-title":"Reumatismo."},{"key":"B17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4081\/reumatismo.2016.885","article-title":"Spine and sacroiliac joints on magnetic resonance imaging in patients with early axial spondyloarthritis: prevalence of lesions and association with clinical and disease activity indices from the Italian group of the SPACE study","volume":"68","author":"Lorenzin","year":"2016","journal-title":"Reumatismo."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1136\/ard.2011.150680","article-title":"Assessment in SpondyloArthritis international Society (ASAS). Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS\/OMERACT MRI study group","volume":"71","author":"Hermann","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/art.21445","article-title":"Spondyloarthritis research consortium of canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis","volume":"53","author":"Maksymowych","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B20","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/art.21337","article-title":"Spondyloarthritis research consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis","volume":"53","author":"Maksymowych","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/ard.2004.020503","article-title":"Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system","volume":"64","author":"Creemers","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"Van der Linden","year":"1984","journal-title":"Arthritis Rheum."},{"key":"B23","first-page":"966","article-title":"Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review","volume":"26","author":"Ruof","year":"1999","journal-title":"J Rheumatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/art.24483","article-title":"The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort","volume":"60","author":"Rudwaleit","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/acr.21688","article-title":"Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?","volume":"64","author":"Kiltz","year":"2012","journal-title":"Arthritis Care Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/art.33465","article-title":"Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis","volume":"64","author":"Poddubnyy","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/imj.12544","article-title":"Advances in classification, basic mechanisms and clinical science in ankylosing spondylitis and axial spondyloarthritis","volume":"45","author":"Robinson","year":"2015","journal-title":"Intern Med J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3899\/jrheum090347","article-title":"Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design","volume":"36","author":"Maksymowych","year":"2009","journal-title":"J Rheumatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/rheumatology\/kei208","article-title":"Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity","volume":"45","author":"Chen","year":"2006","journal-title":"Rheumatology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"E830","DOI":"10.3390\/ijms18040830","article-title":"Spondyloarthritis: matrix metalloproteinasesas biomarkers of pathogenesis and response to tumor necrosis factor (TNF) inhibitors","volume":"18","author":"Moz","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/art.20696","article-title":"Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis","volume":"51","author":"Yang","year":"2004","journal-title":"Arthritis Rheum."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s00296-011-1852-8","article-title":"Role of matrix metalloproteinase-3 (MMP-3) and magnetic resonance imaging of sacroiliitis in assessing disease activity in ankylosing spondylitis","volume":"32","author":"Soliman","year":"2012","journal-title":"Rheumatol Int."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1002\/art.22589","article-title":"Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis","volume":"56","author":"Maksymowych","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1177\/1535370213506435","article-title":"Serological markers in psoriatic arthritis: promising tools","volume":"238","author":"Ramonda","year":"2013","journal-title":"Exp Biol Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e12556","DOI":"10.1371\/journal.pone.0012556","article-title":"Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriasic arthritis: effects of adalimumab versus placebo","volume":"5","author":"van Kuijk","year":"2010","journal-title":"PLoS ONE."},{"key":"B36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10067-006-0283-5","article-title":"Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis","volume":"26","author":"Bal","year":"2007","journal-title":"Clin Rheumatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/rheumatology\/33.10.927","article-title":"Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity","volume":"33","author":"Gratac\u00f3s","year":"1994","journal-title":"Br J Rheumatol."},{"key":"B38","first-page":"828","article-title":"Association between Th-17 cytokine profile and clinical features in patients with spondyloarthritis","volume":"29","author":"Romero-Sanchez","year":"2011","journal-title":"Clin Exp Rheumatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/BOR.0000000000000132","article-title":"The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseases","volume":"27","author":"Sherlock","year":"2015","journal-title":"Curr Opin Rheumatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/art.24568","article-title":"Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis","volume":"60","author":"Shen","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B41","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1186\/ar3370","article-title":"Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response","volume":"13","author":"Appel","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10875-012-9774-0","article-title":"Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-\u03b1 therapy","volume":"33","author":"Xueyi","year":"2013","journal-title":"J Clin Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s00296-009-0883-x","article-title":"Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis","volume":"29","author":"Wang","year":"2009","journal-title":"Rheumatol Int."},{"key":"B44","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jbspin.2006.11.005","article-title":"Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis","volume":"74","author":"Wendling","year":"2007","journal-title":"Joint Bone Spine."},{"key":"B45","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","article-title":"Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2)","volume":"75","author":"Kavanaugh","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"MEASURE 1 Study Group; MEASURE 2 study group. secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"MEASURE 1 study group. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","article-title":"MEASURE 2 study group. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study","volume":"76","author":"Sieper","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10067-010-1647-4","article-title":"Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis","volume":"30","author":"Mei","year":"2011","journal-title":"Clin Rheumatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3109\/03009742.2014.956142","article-title":"Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross sectional comparative study","volume":"44","author":"Sveaas","year":"2015","journal-title":"Scand J Rheumatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3109\/07853890.2011.577093","article-title":"Interleukin-23: a key cytokine in inflammatory diseases","volume":"43","author":"Duvallet","year":"2011","journal-title":"Ann Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jcma.2012.05.006","article-title":"Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis","volume":"75","author":"Chen","year":"2012","journal-title":"J Chin Med Assoc."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/art.37937","article-title":"In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis","volume":"65","author":"Appel","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B55","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/rheumatology\/keu382","article-title":"IL-17- producing CD4+ T cells are increased in early, active axial spondyloarthitis including patients without imaging abnormalities","volume":"54","author":"Jansen","year":"2015","journal-title":"Rheumatology."},{"key":"B56","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00296-010-1655-3","article-title":"Increased plasma levels of IL-21 and IL-23 in spondyloarthritis are not associated with clinical and MRI findings","volume":"32","author":"Andersen","year":"2012","journal-title":"Rheumatol Int."},{"key":"B57","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/art.33396","article-title":"Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis","volume":"64","author":"Noordenbos","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B58","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/art.37704","article-title":"Disease-specific and inflammation-independent stromal alterations in spondylarthritis synovitis","volume":"65","author":"Yeremenko","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e000319","DOI":"10.1136\/rmdopen-2016-000319","article-title":"Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort","volume":"3","author":"Turina","year":"2017","journal-title":"RMD Open."},{"key":"B60","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13075-018-1535-x","article-title":"Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort","volume":"20","author":"de Winter","year":"2018","journal-title":"Arthritis Res Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"R148","DOI":"10.1186\/ar3090","article-title":"Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-\u03b1 blockade in the knee joint","volume":"12","author":"Fiocco","year":"2010","journal-title":"Arthritis Res Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"R136","DOI":"10.1186\/ar4317","article-title":"Th17 and Th22 cells in psoriatic arthritis and psoriasis","volume":"15","author":"Benham","year":"2013","journal-title":"Arthritis Res Ther."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00177\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T11:20:53Z","timestamp":1565176853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00177\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,7]]},"references-count":62,"alternative-id":["10.3389\/fmed.2019.00177"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2019.00177","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,7]]},"article-number":"177"}}